Sodium nitroprusside

Last updated

Sodium nitroprusside
Sodium-nitroprusside-2D.png
Sodium-nitroprusside-sample.jpg
Molecular structure of this compound (top), and a picture of a sample (bottom).
Clinical data
Trade names Nipride, Nitropress, others
Other namesSNP
AHFS/Drugs.com Monograph
License data
Pregnancy
category
  • AU:C
Routes of
administration 		Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 100% (intravenous)
Metabolism By haemoglobin being converted to cyanmethaemoglobin and cyanide ions
Onset of action nearly immediate [3]
Elimination half-life <2 minutes (3 days for thiocyanate metabolite)
Duration of action 1 to 10 minutes [3]
Excretion kidney (100%; as thiocyanate) [4]
Identifiers
  • Sodium pentacyanidonitrosylferrate(III)
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.119.126 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C5FeN6Na2O
Molar mass 261.921 g·mol−1
3D model (JSmol)
Density 1.72 g/cm3
Solubility in water 100 mg/mL (20 °C)
  • [Na+].[Na+].O=N[Fe--](C#N)(C#N)(C#N)(C#N)C#N
  • InChI=1S/5CN.Fe.NO.2Na/c5*1-2;;1-2;;/q;;;;;2*-1;2*+1
  • Key:FPWUWQVZUNFZQM-UHFFFAOYSA-N

Sodium nitroprusside (SNP), sold under the brand name Nitropress among others, is a medication used to lower blood pressure. [3] This may be done if the blood pressure is very high and resulting in symptoms, in certain types of heart failure, and during surgery to decrease bleeding. [3] It is used by continuous injection into a vein. [3] Onset is nearly immediate and effects last for up to ten minutes. [3]

Contents

It is available as a generic medication. [5]

Side effects and mechanism

Common side effects include low blood pressure and cyanide toxicity. [3] Other serious side effects include methemoglobinemia. [3] It is not generally recommended during pregnancy due to concerns of side effects. [6] High doses are not recommended for more than ten minutes. [7] It works by increasing nitric oxide levels in the blood, which increases cGMP levels in cells, and causes dilation of blood vessels. [8] [3]

History, society and culture

Sodium nitroprusside was discovered as early as 1850 and found to be useful in medicine in 1928. [8] [9] It is on the World Health Organization's List of Essential Medicines. [10] [11] Sodium nitroprusside is light sensitive, so it needs to be shielded from light to prevent degradation. [12]

Medical use

Sodium nitroprusside is intravenously infused in cases of acute hypertensive crises. [13] [14] Its effects are usually seen within a few minutes. [4]

Nitric oxide reduces both total peripheral resistance and venous return, thus decreasing both preload and afterload. So, it can be used in severe congestive heart failure where this combination of effects can act to increase cardiac output. In situations where cardiac output is normal, the effect is to reduce blood pressure. [13] [15] It is sometimes also used to induce hypotension (to reduce bleeding) for surgical procedures (for which it is also FDA, TGA, and MHRA labelled). [13] [14] [16]

The medication is extremely beneficial for use in medical patients because the effects of the medication will directly stop the second that it stops being infused. This is due to the metabolism of the drug, and the rapid inactivation to thiocyanate once conversion of the drug stops.

This compound has also been used as a treatment for aortic valve stenosis, [17] oesophageal varices, [18] myocardial infarction, [19] pulmonary hypertension, [20] [21] [22] respiratory distress syndrome in the newborn, [23] [24] shock, [24] and ergot toxicity. [25]

Adverse effects

Adverse effects by incidence and severity [13] [15] [26]

Common

Unknown frequency

Serious

Contraindications

Sodium nitroprusside should not be used for compensatory hypertension (e.g. due to an arteriovenous stent or coarctation of the aorta). [15] It should not be used in patients with inadequate cerebral circulation or in patients who are near death. It should not be used in patients with vitamin B12 deficiency, anaemia, severe renal disease, or hypovolaemia. [15] Patients with conditions associated with a higher cyanide/thiocyanate ratio (e.g. congenital (Leber's) optic atrophy, tobacco amblyopia) should only be treated with sodium nitroprusside with great caution. [15] Its use in patients with acute congestive heart failure associated with reduced peripheral resistance is also not recommended. [15] Its use in hepatically impaired individuals is also not recommended, as is its use in cases of pre-existing hypothyroidism. [13]

Its use in pregnant women is advised against, although the available evidence suggests it may be safe, provided maternal pH and cyanide levels are closely monitored. [15] [27] Some evidence suggests sodium nitroprusside use in critically ill children may be safe, even without monitoring of cyanide level. [28]

Interactions

The only known drug interactions are pharmacodynamic in nature, that is it is possible for other antihypertensive drugs to reduce the threshold for dangerous hypotensive effects to be seen. [15]

Overdose

Due to its cyanogenic nature, overdose may be particularly dangerous. Treatment of sodium nitroprusside overdose includes the following: [15] [29]

Haemodialysis is ineffective for removing cyanide from the body but it can be used to remove most of the thiocyanate produced from the above procedure. [15]

Toxicology

The cyanide can be detoxified by reaction with a sulfur-donor such as thiosulfate, catalysed by the enzyme rhodanese. [30] In the absence of sufficient thiosulfate, cyanide ions can quickly reach toxic levels. [30] Hydroxocobalamin can be administered to reduce the risk of thiocyanate toxicity induced by nitroprusside. [31]

SpeciesLD50 (mg/kg) for oral administration [32] LD50 (mg/kg) for IV administration [15] LD50 (mg/kg) for skin administration [32]
Mouse438.4 ?
Rat30011.2>2000
Rabbit ?2.8 ?
Dog ?5 ?

Mechanism of action

As a result of its breakdown to nitric oxide (NO), sodium nitroprusside has potent vasodilating effects on arterioles and venules (arterial more than venous), whereas other nitrates exhibit more selectivity for veins (e.g. nitroglycerin). [13] [15] [26] [33]

Sodium nitroprusside breaks down in circulation to release nitric oxide (NO). [8] It does this by binding to oxyhaemoglobin to release cyanide, methaemoglobin and nitric oxide. [8] NO activates guanylate cyclase in vascular smooth muscle and increases intracellular production of cGMP. cGMP activates protein kinase G which activates phosphatases which inactivate myosin light chains. [34] Myosin light chains are involved in smooth muscle contraction. The result is vascular smooth muscle relaxation, which allow vessels to dilate. [34] This mechanism is similar to that of phosphodiesterase 5 (PDE5) inhibitors such as sildenafil (Viagra) and tadalafil (Cialis), which elevate cGMP concentration by inhibiting its degradation by PDE5. [35]

A role for NO in various common psychiatric disorders including schizophrenia, [36] [37] [38] [39] bipolar disorder [40] [41] [42] and major depressive disorder [43] [44] [45] has been proposed and supported by several clinical findings. These findings may also implicate the potential of drugs that alter NO signalling such as SNP in their treatment. [38] [44] Such a role is also supported by the findings of the recent SNP clinical trial. [46]

Structure and properties

Structure of sodium nitroprusside in the solid state, obtained by neutron diffraction Sodium-nitroprusside-xtal-3D-balls-A.png
Structure of sodium nitroprusside in the solid state, obtained by neutron diffraction
Space filling model of sodium nitroprusside Nitroprusside-anion-from-xtal-3D-vdW.png
Space filling model of sodium nitroprusside

Nitroprusside is an inorganic compound with the chemical formula Na2[Fe(CN)5NO], usually encountered as the dihydrate, Na2[Fe(CN)5NO]·2H2O. [47] This red-colored sodium salt dissolves in water or ethanol to give solutions containing the free complex dianion [Fe(CN)5NO]2−.

Nitroprusside is a complex anion that features an octahedral iron(II) centre surrounded by five tightly bound cyanide ligands and one linear nitric oxide ligand (Fe-N-O angle = 176.2 ° [48] ). The anion possesses idealized C4vsymmetry.

Due to the linear Fe-N-O angle, the relatively short N-O distance of 113 pm [48] and the relatively high stretching frequency of 1947 cm−1, the complex is formulated as containing an NO+ ligand. [49] Consequently, iron is assigned an oxidation state of 2+. The iron center has a diamagnetic low-spin d6 electron configuration, although a paramagnetic long-lived metastable state has been observed by EPR spectroscopy. [50]

The chemical reactions of sodium nitroprusside are mainly associated with the NO ligand. [51] For example, addition of S2− ion to [Fe(CN)5(NO)]2− produces the violet colour [Fe(CN)5(NOS)]4− ion, which is the basis for a sensitive test for S2− ions. An analogous reaction also exists with OH− ions, giving [Fe(CN)5(NO2)]4−. [49] Roussin's red salt (K2[Fe2S2(NO)4]) and Roussin's black salt (NaFe4S3(NO)7) are related iron nitrosyl complexes. The former was first prepared by treating nitroprusside with sulfur. [52]

Preparation

Sodium nitroprusside can be synthesized by digesting a solution of potassium ferrocyanide in water with nitric acid, followed by neutralization with sodium carbonate: [53]

Alternatively, the nitrosyl ligand can be introduced using nitrite: [49]

Other uses

Sodium nitroprusside spectrum is used to calibrate Mossbauer spectrometers Sodium nitroprusside Mossbauer spectrum.svg
Sodium nitroprusside spectrum is used to calibrate Mössbauer spectrometers

Sodium nitroprusside is often used as a reference compound for the calibration of Mössbauer spectrometers. [54] Sodium nitroprusside crystals are also of interest for optical storage. For this application, sodium nitroprusside can be reversibly promoted to a metastable excited state by blue-green light, and de-excited by heat or red light. [55]

In physiology research, sodium nitroprusside is frequently used to test endothelium-independent vasodilation. Iontophoresis, for example, allows local administration of the drug, preventing the systemic effects listed above but still inducing local microvascular vasodilation. Sodium nitroprusside is also used in microbiology, where it has been linked with the dispersal of Pseudomonas aeruginosa biofilms by acting as a nitric oxide donor. [56] [57]

Analytical reagent

Sodium nitroprusside is also used as an analytical reagent under the name sodium nitroferricyanide for the detection of methyl ketones, amines, and thiols. It is also used as a catalyst in the quantitative determination of ammonia in water samples via the phenate method. [58]

Ketones

The nitroprusside reaction is used for the identification of ketones in urine testing. [59] Sodium nitroprusside was found to give a reaction with acetone or creatine under basic conditions in 1882. Rothera refined this method by the use of ammonia in place of sodium or potassium hydroxide. The reaction was now specific for methyl ketones. Addition of ammonium salts (e.g. ammonium sulfate) improved the sensitivity of the test, too. [60]

In this test, known as Rothera's test, methyl ketones (CH3C(=O)-) under alkaline conditions give bright red coloration (see also iodoform test). Rothera's test was initially applied to detecting ketonuria (a symptom of diabetes) in urine samples. This reaction is now exploited in the form of urine test strips (e.g. "Ketostix"). [61]

Thiols and cysteine

The nitroprusside reaction is a chemical test used to detect the presence of thiol groups of cysteine in proteins. Proteins with the free thiol group give a red colour when added to a solution of sodium nitroprusside in aqueous ammonia. Some proteins test positive when denatured, indicating that thiol groups are liberated. [62] [63] [64]

Sodium nitroprusside is used in a separate urinalysis test known as the cyanide nitroprusside test or Brand's test. In this test, sodium cyanide is added first to urine and let stand for about 10 minutes. In this time, disulfide bonds will be broken by the released cyanide. The destruction of disulfide bonds liberates cysteine from cystine as well as homocysteine from homocystine. Next, sodium nitroprusside is added to the solution and it reacts with the newly freed sulfhydryl groups. The test will turn a red/purple colour if the test is positive, indicating significant amounts of amino acids were in the urine (aminoaciduria). Cysteine, cystine, homocysteine, and homocystine all react when present in the urine when this test is performed. This test can indicate inborn errors of amino acid transporters such as cystinuria, which results from pathology in the transport of dibasic amino acids. [65]

Amines

Sodium nitroprusside is also used to detect amines, including those in illicit drugs. This compound is thus used as a stain to indicate amines in thin layer chromatography. [66] Sodium nitroprusside is similarly used as a presumptive test for the presence of alkaloids (amine-containing natural products) common in illicit substances. [67] The test, called Simon's test, is performed by adding 1 volume of a solution of sodium nitroprusside and acetaldehyde in deionized water to a suspected drug, followed by the addition of 2 volumes of an aqueous sodium carbonate solution. The test turns blue for some secondary amines. The most common secondary amines encountered in forensic chemistry include 3,4-methylenedioxymethamphetamine (MDMA, the main component in ecstasy) and phenethylamines such as methamphetamine. Sodium nitroprusside is also useful in the identification the mercaptans (thiol groups) in the nitroprusside reaction.

History

Sodium nitroprusside is primarily used as a vasodilator. It was first used in human medicine in 1928. [8] By 1955, data on its safety during short-term use in people with severe hypertension had become available. [8] Despite this, due to difficulties in its chemical preparation, it was not finally approved by the US FDA until 1974 for the treatment of severe hypertension. [8] By 1993, its popularity had grown such that total sales in the US had totalled US$2 million. [8]

Related Research Articles

<span class="mw-page-title-main">Cyanide</span> Any molecule with a cyano group (–C≡N)

In chemistry, a cyanide is a chemical compound that contains a C≡N functional group. This group, known as the cyano group, consists of a carbon atom triple-bonded to a nitrogen atom.

<span class="mw-page-title-main">Potassium ferrocyanide</span> Chemical compound

Potassium ferrocyanide is the inorganic compound with formula K4[Fe(CN)6]·3H2O. It is the potassium salt of the coordination complex [Fe(CN)6]4−. This salt forms lemon-yellow monoclinic crystals.

<span class="mw-page-title-main">Nitric oxide</span> Colorless gas with the formula NO

Nitric oxide is a colorless gas with the formula NO. It is one of the principal oxides of nitrogen. Nitric oxide is a free radical: it has an unpaired electron, which is sometimes denoted by a dot in its chemical formula. Nitric oxide is also a heteronuclear diatomic molecule, a class of molecules whose study spawned early modern theories of chemical bonding.

The nitrite ion has the chemical formula NO−
2. Nitrite is widely used throughout chemical and pharmaceutical industries. The nitrite anion is a pervasive intermediate in the nitrogen cycle in nature. The name nitrite also refers to organic compounds having the –ONO group, which are esters of nitrous acid.

<span class="mw-page-title-main">Sodium nitrite</span> Chemical compound

Sodium nitrite is an inorganic compound with the chemical formula NaNO2. It is a white to slightly yellowish crystalline powder that is very soluble in water and is hygroscopic. From an industrial perspective, it is the most important nitrite salt. It is a precursor to a variety of organic compounds, such as pharmaceuticals, dyes, and pesticides, but it is probably best known as a food additive used in processed meats and (in some countries) in fish products.

<span class="mw-page-title-main">Bumetanide</span> A loop diuretic

Bumetanide, sold under the brand name Bumex among others, is a medication used to treat swelling and high blood pressure. This includes swelling as a result of heart failure, liver failure, or kidney problems. It may work for swelling when other medications have not. For high blood pressure it is not a preferred treatment. It is taken by mouth, or by injection into a vein or muscle. Effects generally begin within an hour and last for about six hours.

<span class="mw-page-title-main">Thiocyanate</span> Ion (S=C=N, charge –1)

Thiocyanates are salts containing the thiocyanate anion [SCN]−. [SCN]− is the conjugate base of thiocyanic acid. Common salts include the colourless salts potassium thiocyanate and sodium thiocyanate. Mercury(II) thiocyanate was formerly used in pyrotechnics.

Pseudohalogens are polyatomic analogues of halogens, whose chemistry, resembling that of the true halogens, allows them to substitute for halogens in several classes of chemical compounds. Pseudohalogens occur in pseudohalogen molecules, inorganic molecules of the general forms Ps–Ps or Ps–X, such as cyanogen; pseudohalide anions, such as cyanide ion; inorganic acids, such as hydrogen cyanide; as ligands in coordination complexes, such as ferricyanide; and as functional groups in organic molecules, such as the nitrile group. Well-known pseudohalogen functional groups include cyanide, cyanate, thiocyanate, and azide.

The sodium fusion test, or Lassaigne's test, is used in elemental analysis for the qualitative determination of the presence of foreign elements, namely halogens, nitrogen, and sulfur, in an organic compound. It was developed by J. L. Lassaigne.

Secondary hypertension is a type of hypertension which by definition is caused by an identifiable underlying primary cause. It is much less common than the other type, called essential hypertension, affecting only 5-10% of hypertensive patients. It has many different causes including endocrine diseases, kidney diseases, and tumors. It also can be a side effect of many medications.

<span class="mw-page-title-main">Copper(I) cyanide</span> Chemical compound

Copper(I) cyanide is an inorganic compound with the formula CuCN. This off-white solid occurs in two polymorphs; impure samples can be green due to the presence of Cu(II) impurities. The compound is useful as a catalyst, in electroplating copper, and as a reagent in the preparation of nitriles.

<span class="mw-page-title-main">Nitroso</span> Class of functional groups with a –N=O group attached

In organic chemistry, nitroso refers to a functional group in which the nitric oxide group is attached to an organic moiety. As such, various nitroso groups can be categorized as C-nitroso compounds, S-nitroso compounds, N-nitroso compounds, and O-nitroso compounds.

A nitrate test is a chemical test used to determine the presence of nitrate ion in solution. Testing for the presence of nitrate via wet chemistry is generally difficult compared with testing for other anions, as almost all nitrates are soluble in water. In contrast, many common ions give insoluble salts, e.g. halides precipitate with silver, and sulfate precipitate with barium.

<span class="mw-page-title-main">Metal nitrosyl complex</span> Complex of a transition metal bonded to nitric oxide: Me–NO

Metal nitrosyl complexes are complexes that contain nitric oxide, NO, bonded to a transition metal. Many kinds of nitrosyl complexes are known, which vary both in structure and coligand.

<span class="mw-page-title-main">Nitrosyl chloride</span> Chemical compound

Nitrosyl chloride is the chemical compound with the formula NOCl. It is a yellow gas that is commonly encountered as a component of aqua regia, a mixture of 3 parts concentrated hydrochloric acid and 1 part of concentrated nitric acid. It is a strong electrophile and oxidizing agent. It is sometimes called Tilden's reagent, after William A. Tilden, who was the first to produce it as a pure compound.

<span class="mw-page-title-main">Cyanide poisoning</span> Broad-spectrum poisoning

Cyanide poisoning is poisoning that results from exposure to any of a number of forms of cyanide. Early symptoms include headache, dizziness, fast heart rate, shortness of breath, and vomiting. This phase may then be followed by seizures, slow heart rate, low blood pressure, loss of consciousness, and cardiac arrest. Onset of symptoms usually occurs within a few minutes. Some survivors have long-term neurological problems.

<span class="mw-page-title-main">Roussin's red salt</span> Chemical compound

Roussin's red salt is the inorganic compound with the formula K2[Fe2S2(NO)4]. This metal nitrosyl was first described by Zacharie Roussin in 1858, making it one of the first synthetic iron-sulfur clusters.

<span class="mw-page-title-main">Nitrovasodilator</span> Drug that causes vasodilation by releasing nitric oxide

A nitrovasodilator is a pharmaceutical agent that causes vasodilation by donation of nitric oxide (NO), and is mostly used for the treatment and prevention of angina pectoris.

Biological functions of nitric oxide are roles that nitric oxide plays within biology.

<span class="mw-page-title-main">Transition metal nitrite complex</span> Chemical complexes containing one or more –NO₂ ligands

In organometallic chemistry, transition metal complexes of nitrite describes families of coordination complexes containing one or more nitrite ligands. Although the synthetic derivatives are only of scholarly interest, metal-nitrite complexes occur in several enzymes that participate in the nitrogen cycle.

References

  1. ↑ "Nitroprusside Rmb, Nitroprusside Sxp, Nitroprusside Tlb (Southern XP IP Pty Ltd)". Therapeutic Goods Administration (TGA). 5 December 2022. Retrieved 9 April 2023.
  2. ↑ "Sodium nitroprusside Baxter (Baxter Healthcare Pty Ltd)". Therapeutic Goods Administration (TGA). 2 June 2023. Retrieved 10 September 2023.
  3. 1 2 3 4 5 6 7 8 9 "Sodium Nitroprusside". The American Society of Health-System Pharmacists. Archived from the original on 21 December 2016. Retrieved 8 December 2016.
  4. 1 2 Brunton L, Chabner B, Knollman B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (12th ed.). New York: McGraw-Hill Professional. ISBN   978-0-07-162442-8.
  5. ↑ "First Generic Drug Approvals". U.S. Food and Drug Administration. 17 October 2022. Retrieved 28 November 2022.
  6. ↑ "Nitroprusside Pregnancy and Breastfeeding Warnings". Drugs.com. 2018. Archived from the original on 21 December 2016. Retrieved 14 December 2016.
  7. ↑ World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 283. hdl: 10665/44053 . ISBN   9789241547659.
  8. 1 2 3 4 5 6 7 8 Friederich JA, Butterworth JF (July 1995). "Sodium nitroprusside: twenty years and counting". Anesthesia and Analgesia. Lippincott Williams & Wilkins. 81 (1): 152–162. doi: 10.1213/00000539-199507000-00031 . PMID   7598246.
  9. ↑ Nichols DG, Greeley WJ, Lappe DG, Ungerleider RM, Cameron DE, Spevak PJ, Wetzel RC (2006). Critical Heart Disease in Infants and Children (2 ed.). Elsevier Health Sciences. p. 192. ISBN   9780323070072.
  10. ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  11. ↑ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl: 10665/345533 . WHO/MHP/HPS/EML/2021.02.
  12. ↑ Lip G (2007). Comprehensive Hypertension. Mosby. pp. 761–774. doi:10.1016/B978-0-323-03961-1.X5001-6. ISBN   978-0-323-03961-1.
  13. 1 2 3 4 5 6 "NITROPRESS (sodium nitroprusside) injection, solution, concentrate". DailyMed. Hospira. January 2011. Archived from the original on 3 December 2013. Retrieved 20 November 2013.
  14. 1 2 Joint Formulary Committee (2013). British National Formulary (BNF) (65th ed.). London, UK: Pharmaceutical Press. ISBN   978-0-85711-084-8.
  15. 1 2 3 4 5 6 7 8 9 10 11 12 "DBL® SODIUM NITROPRUSSIDE FOR INJECTION BP" (PDF). TGA eBusiness Services. Hospira Australia Pty Ltd. 22 April 2010. Archived from the original on 10 September 2017. Retrieved 20 November 2013.
  16. ↑ Rossi S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN   978-0-9805790-9-3.
  17. ↑ Ikram H, Low CJ, Crozier IG, Shirlaw T (February 1992). "Hemodynamic effects of nitroprusside on valvular aortic stenosis". Am. J. Cardiol. 69 (4): 361–366. doi:10.1016/0002-9149(92)90234-P. PMID   1734649.
  18. ↑ Sirinek KR, Adcock DK, Levine BA (January 1989). "Simultaneous infusion of nitroglycerin and nitroprusside to offset adverse effects of vasopressin during portosystemic shunting". Am. J. Surg. 157 (1): 33–37. doi:10.1016/0002-9610(89)90416-9. PMID   2491934.
  19. ↑ Yusuf S, Collins R, MacMahon S, Peto R (May 1988). "Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials". Lancet . 331 (8594): 1088–92. doi:10.1016/S0140-6736(88)91906-X. PMID   2896919. S2CID   27098017.
  20. ↑ Costard-Jäckle A, Fowler MB (January 1992). "Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group". J. Am. Coll. Cardiol. 19 (1): 48–54. doi: 10.1016/0735-1097(92)90050-W . PMID   1729345.
  21. ↑ Knapp E, Gmeiner R (February 1977). "Reduction of pulmonary hypertension by nitroprusside". International Journal of Clinical Pharmacology and Biopharmacy. 15 (2): 75–80. PMID   885667.
  22. ↑ Freitas AF Jr, Bacal F, Oliveira Júnior Jde L, Fiorelli AI, et al. (September 2012). "Sildenafil vs. sodium before nitroprusside for the pulmonary hypertension reversibility test before cardiac transplantation". Arquivos Brasileiros de Cardiologia. 99 (3): 848–56. doi: 10.1590/S0066-782X2012005000076 . PMID   22898992.
  23. ↑ Palhares DB, Figueiredo CS, Moura AJ (January 1998). "Endotracheal inhalatory sodium nitroprusside in severely hypoxic newborns". Journal of Perinatal Medicine. 26 (3): 219–224. doi:10.1515/jpme.1998.26.3.219. PMID   9773383. S2CID   31630912.
  24. 1 2 Benitz WE, Malachowski N, Cohen RS, Stevenson DK, Ariagno RL, Sunshine P (January 1985). "Use of sodium nitroprusside in neonates: efficacy and safety". J. Pediatr. Elsevier Mosby. 106 (1): 102–110. doi:10.1016/S0022-3476(85)80477-7. PMID   3917495.
  25. ↑ Merhoff GC, Porter JM (November 1974). "Ergot intoxication: historical review and description of unusual clinical manifestations". Ann. Surg. 180 (5): 773–779. doi:10.1097/00000658-197411000-00011. PMC   1343691 . PMID   4371616.
  26. 1 2 "Nipride RTU, Nitropress (nitroprusside sodium) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 3 December 2013. Retrieved 20 November 2013.
  27. ↑ Sass N, Itamoto CH, Silva MP, Torloni MR, et al. (March 2007). "Does sodium nitroprusside kill babies? A systematic review". Sao Paulo Medical Journal. 125 (2): 108–111. doi: 10.1590/S1516-31802007000200008 . PMID   17625709.
  28. ↑ Thomas C, Svehla L, Moffett BS (September 2009). "Sodium nitroprusside induced cyanide toxicity in pediatric patients". Expert Opinion on Drug Safety . 8 (5): 599–602. doi:10.1517/14740330903081717. PMID   19645589. S2CID   5334690.
  29. ↑ Rindone JP, Sloane EP (April 1992). "Cyanide toxicity from sodium nitroprusside: Risks and management". Ann. Pharmacother. 26 (4): 515–519. doi:10.1177/106002809202600413. PMID   1533553. S2CID   35273460.
  30. 1 2 "Nitropress (Nitroprusside Sodium) Drug Information: Clinical Pharmacology – Prescribing Information". RxList. RxList Inc. 4 July 2009. Archived from the original on 21 April 2014. Retrieved 21 November 2013.
  31. ↑ Zerbe NF, Wagner BK (March 1993). "Use of vitamin B12 in the treatment and prevention of nitroprusside-induced cyanide toxicity". Critical Care Medicine. 21 (3): 465–467. doi:10.1097/00003246-199303000-00027. PMID   8440119. S2CID   43866386.
  32. 1 2 "Material Safety Data Sheet Sodium nitroprusside, ACS" (PDF). Qorpak. Berlin Packaging. 1 August 2006. Archived (PDF) from the original on 24 September 2015. Retrieved 21 November 2013.
  33. ↑ "Nitropress- sodium nitroprusside injection, solution, concentrate". labeling.pfizer.com. Retrieved 1 August 2019.
  34. 1 2 Murad F (July 1986). "Cyclic Guanosine Monophosphate as a Mediator of Vasodilation". J. Clin. Investig. 78 (1): 1–5. doi:10.1172/JCI112536. PMC   329522 . PMID   2873150.
  35. ↑ Kukreja RC, Salloum FN, Das A (May 2012). "Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection". Journal of the American College of Cardiology . 59 (22): 1921–1927. doi:10.1016/j.jacc.2011.09.086. PMC   4230443 . PMID   22624832.
  36. ↑ Bernstein HG, Bogerts B, Keilhoff G (October 2005). "The many faces of nitric oxide in schizophrenia. A review". Schizophrenia Research . 78 (1): 69–86. doi:10.1016/j.schres.2005.05.019. PMID   16005189. S2CID   42764954.
  37. ↑ Silberberg G, Ben-Shachar D, Navon R (October 2010). "Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder". Am. J. Med. Genet. B . 153B (7): 1318–1328. doi:10.1002/ajmg.b.31112. PMID   20645313. S2CID   205325558.
  38. 1 2 Bernstein HG, Keilhoff G, Steiner J, Dobrowolny H, et al. (November 2011). "Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy". CNS & Neurological Disorders Drug Targets. 10 (7): 792–807. doi:10.2174/187152711798072392. PMID   21999729.
  39. ↑ Coyle JT (July 2013). "Nitric Oxide and Symptom Reduction in Schizophrenia". JAMA Psychiatry . 70 (7): 664–665. doi:10.1001/jamapsychiatry.2013.210. PMID   23699799.
  40. ↑ Yanik M, Vural H, Tutkun H, Zoroğlu SS, et al. (February 2004). "The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder". European Archives of Psychiatry and Clinical Neuroscience . 254 (1): 43–47. doi:10.1007/s00406-004-0453-x. PMID   14991378. S2CID   24592011.
  41. ↑ Fontoura PC, Pinto VL, Matsuura C, Resende Ade C, et al. (October 2012). "Defective Nitric Oxide–Cyclic Guanosine Monophosphate Signaling in Patients With Bipolar Disorder: A Potential Role for Platelet Dysfunction". Psychosom. Med. 74 (8): 873–877. doi:10.1097/PSY.0b013e3182689460. PMID   23023680. S2CID   37347633.
  42. ↑ Bielau H, Brisch R, Bernard-Mittelstaedt J, Dobrowolny H, et al. (June 2012). "Immunohistochemical evidence for impaired nitric oxide signaling of the locus coeruleus in bipolar disorder". Brain Research . 1459: 91–99. doi:10.1016/j.brainres.2012.04.022. PMID   22560594. S2CID   25790297.
  43. ↑ Gałecki P, Maes M, Florkowski A, Lewiński A, Gałecka E, Bieńkiewicz M, Szemraj J (March 2011). "Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder". Journal of Affective Disorders . 129 (1–3): 175–82. doi:10.1016/j.jad.2010.09.005. PMID   20888049.
  44. 1 2 Dhir A, Kulkarni SK (April 2011). "Nitric oxide and major depression". Nitric Oxide . 24 (3): 125–131. doi:10.1016/j.niox.2011.02.002. PMID   21335097.
  45. ↑ Savaş HA, Herken H, Yürekli M, Uz E, et al. (2002). "Possible role of nitric oxide and adrenomedullin in bipolar affective disorder". Neuropsychobiology . 45 (2): 57–61. doi:10.1159/000048677. PMID   11893860. S2CID   7505572.
  46. ↑ Hallak JE, Maia-de-Oliveira JP, Abrao J, Evora PR, et al. (8 May 2013). "Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: A randomized, double-blind, placebo-controlled trial". JAMA Psychiatry. 70 (7): E3–E5. doi: 10.1001/jamapsychiatry.2013.1292 . PMID   23699763.
  47. ↑ Butler AR, Megson IL (2002). "Non-Heme Iron Nitrosyls in Biology". Chem. Rev. 102 (4): 1155–1165. doi:10.1021/cr000076d. PMID   11942790.
  48. 1 2 Navaza A, Chevrier G, Alzari PM, Aymonino PJ (1989). "Single-crystal neutron diffraction structure of sodium pentacyanonitrosylferrate(2-) (sodium nitroprusside) dihydrate". Acta Crystallogr. C . 45 (6): 839–841. Bibcode:1989AcCrC..45..839N. doi:10.1107/S0108270188013691.
  49. 1 2 3 Housecroft CE, Sharpe AG (2008). "Chapter 22: d-Block metal chemistry: the first row metals". Inorganic Chemistry (3rd ed.). Pearson. p. 721. ISBN   978-0-13-175553-6.
  50. ↑ Tritt-Goc J, Piślewski N, Hoffmann SK (1997). "EPR evidence of the paramagnetism of a long-living metastable excited state of a sodium nitroprusside single crystal". Chemical Physics Letters . 268 (5–6): 471–474. Bibcode:1997CPL...268..471T. doi:10.1016/S0009-2614(97)00217-0.
  51. ↑ Coppens P, Novozhilova I, Kovalevsky A (2002). "Photoinduced Linkage Isomers of Transition-Metal Nitrosyl Compounds and Related Complexes". Chemical Reviews . 102 (4): 861–883. doi:10.1021/cr000031c. PMID   11942781.
  52. ↑ Reihlen H, von Friedolsheim A (1927). "Über komplexe Stickoxydverbindungen und das sogenannte einwertige Eisen". Justus Liebigs Annalen der Chemie . 457: 71–82. doi:10.1002/jlac.19274570103.
  53. ↑ Brauer G, ed. (1963). "Sodium Nitrosyl Cyanoferrate". Handbook of Preparative Inorganic Chemistry. Vol. 2 (2nd ed.). New York: Academic Press. p. 1768. LCCN   63014307.
  54. ↑ Spijkerman JJ, Snediker DK, Ruegg FC, DeVoe JR. NBS Misc. Publ. 260-13: Mossbauer Spectroscopy Standard for the Chemical Shift of Iron Compounds (PDF). National Institute of Standards and Technology. Archived (PDF) from the original on 4 March 2016.
  55. ↑ Woike T, Krasser W, Bechthold PS, Haussühl S (1984). "Extremely Long-Living Metastable State of Na2[Fe(CN)5NO]·2H2O Single Crystals: Optical". Physical Review Letters . 53 (18): 1767–1770. Bibcode:1984PhRvL..53.1767W. doi:10.1103/PhysRevLett.53.1767.
  56. ↑ Barraud N, Hassett DJ, Hwang SH, Rice SA, et al. (2006). "Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa". Journal of Bacteriology . 188 (21): 7344–53. doi:10.1128/JB.00779-06. PMC   1636254 . PMID   17050922.
  57. ↑ Chua SL, Liu Y, Yam JKH, Tolker-Nielsen T, et al. (2014). "Dispersed cells represent a distinct stage in the transition from bacterial biofilm to planktonic lifestyles". Nature Communications . 5: 4462. Bibcode:2014NatCo...5.4462C. doi: 10.1038/ncomms5462 . PMID   25042103.
  58. ↑ Rice EW, Bridgewater L, Easton AD, eds. (2017). Standard Methods for the Examination of Water and Wastewater. American Public Health Association. pp. 4500-NH3 F., 4–114. ISBN   978-0-87553-287-5.
  59. ↑ Kaneko JJ, Harvey JW, Bruss ML, eds. (2008). Clinical Biochemistry of Domestic Animals (6th ed.). Academic Press. p. 98. ISBN   9780080568829.
  60. ↑ Rothera AC (1908). "Note on the sodium nitro-prusside reaction for acetone". J. Physiol. (Lond.) . 37 (5–6): 491–494. doi:10.1113/jphysiol.1908.sp001285. PMC   1533603 . PMID   16992945.
  61. ↑ Comstock JP, Garber AJ (1990). "Chapter 140. Ketonuria". In Walker HK, Hall WD, Hurst JW (eds.). Clinical Methods: The History, Physical, and Laboratory Examinations (3rd ed.). Boston: Butterworths. ISBN   9780409900774. PMID   21250091 – via NCBI Bookshelf.
  62. ↑ Chatterjea MN (1 January 2004). Textbook of Biochemistry for Dental/Nursing/Pharmacy Students. India: Jaypee Brothers Publishers. p. 51. ISBN   978-81-8061-204-6. OCLC   1027921456.
  63. ↑ Das D (1980). Biochemistry. Academic Publishers. p. 56. ISBN   978-93-80599-17-5.
  64. ↑ Joshi RA (2006). Question Bank of Biochemistry. New Age International. p. 64. ISBN   978-81-224-1736-4.
  65. ↑ Finocchiaro R, D'Eufemia P, Celli M, Zaccagnini M, et al. (1998). "Usefulness of cyanide-nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure". Journal of Urology and Research. 26 (6): 401–5. doi:10.1007/s002400050076. PMID   9879820. S2CID   28323457.
  66. ↑ "TLC Visualization Reagents" (PDF). École Polytechnique Fédérale de Lausanne. Archived from the original (PDF) on 13 May 2015. Retrieved 21 November 2013.
  67. ↑ O'Neala CL, Croucha DJ, Fatahb AA (2000). "Validation of twelve chemical spot tests for the detection of drugs of abuse". Forensic Science International . 109 (3): 189–201. doi:10.1016/S0379-0738(99)00235-2. PMID   10725655.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.